Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eli Lilly ‘awaits decision’ for prasugrel

Eli Lilly ‘awaits decision’ for prasugrel

6th June 2008

Pharmaceutical giant Eli Lilly has just ten days before it will be told whether its drug prasugre – which is said to relieve heart problems – has been approved.

The Food and Drug Administration (FDA) is set to make a decision on June 26th on what would potentially mark the first new drug unveiled by the firm in three years.

Researched undertaken by Eli Lilly and Japanese developer Daiichi Sankyo found that prasugrel was better than Plavix – the second-best selling drug in the world – at averting blood clots and heart problems.

However, concerns have been raised over some of the drug’s side effects with a small group of those tested seeing the risk of serious bleeding increase after its use.

Analyst Les Funtleyder said however: “The side effects aren’t so onerous that it’s a dangerous drug.”

The drugs firm will be waiting with bated breath for the conclusion of the FDA – with the medicine, if approved, set to be worth a total of 306 million pounds annually.

Other drugs currently being trialled by Eli Lilly include enzastaurin, a treatment for non-hodgkin’s lymphoma and arzoxifene, believed to help prevent osteoporosis and breast cancer.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.